{"paper_id":"b4b8bfcb-b244-4f51-a97e-d50a66649027","body_text":"S-WG has served as a consultant or speaker within the past 12 months to E3A HealthCare, FimmCyte AG, Maipl, ReproNova, and Ziwig. Neither S-WG nor his family members hold issued stock directly or indirectly in any of these companies. S-WG holds non-exercised options in Heranova. S-WG is an Associate Editor of  Reproduction & Fertility  and was not involved in the review or editorial process for this paper, on which he is listed as an author. All others have nothing to declare.\n\nThis research was supported by grant 202440057 (JN) from the Clinical Research Project of Shanghai Municipal Health Commission.\n\nS-WG and XL contributed to conceptualization. S-WG and JN contributed to methodology and resources. JN and YY contributed to validation, investigation, and data curation. S-WG contributed to formal analysis, visualization, and writing of the original draft. S-WG, JN, YY, XL, and PRK reviewed and edited the manuscript. JN and XL contributed to supervision and project administration. JN contributed to funding acquisition. All authors have read and agreed to the published version of the manuscript.\n\nAll procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki 1964 and its later amendments. Informed consent was obtained from all patients for being included in the study. This study was approved by the Institutional Ethics Review Board of Shanghai OB/GYN Hospital, Fudan University (No. 2024-93). Each patient enrolled in this study signed an informed consent for all the procedures and to allow data collection and analysis for research purposes.","source_license":"CC0","license_restricted":false}